Characterization of Residual Impurities in Gene Therapy Drug Products
Jessica Townsend, at Intellia Therapeutics Eric S. Bishop, at Cygnus Technologies
About this talk
Characterization of residual impurities for gene therapy drug products is particularly challenging due to the complex nature of the final products as well as the complicated processes required to manufacture them. As these products advance through clinical development, the identification, characterization, and control of the process- and product-related impurities are important to define early on, and require careful assessment of impurity clearance and risk related to each impurity. This talk will focus on risk assessment and characterization of product-related impurities in lentiviral vector-based gene therapy products.
BioPharma Webinars aims to keep its global audience abreast of all developments in the areas of Drug Development, Manufacturing, Quality Assurance, Outsourcing and Regulatory Affairs, with only the highest quality webinars, presented by the most respected people, working with companies in Pharmaceutical, Biopharmaceutical, Biologics and Biotech Industry.…